Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01867424 · ClinicalTrials.gov registry record · Phase 2

Gadoxetate Enhanced Imaging Study to Detect Prostate Cancer

A Phase 2 study of Prostate Cancer, sponsored by National Cancer Institute (NCI).

Completed
Registry status
Phase 2
Development phase
24
Enrollment target
1
Study location

NCT01867424: Completed Phase 2 study of Prostate Cancer, sponsored by National Cancer Institute (NCI).

NCT01867424 is a Phase 2 study of Prostate Cancer that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 24 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01867424, a Phase 2 study of Prostate Cancer, has completed, sponsored by National Cancer Institute (NCI).

COMPLETED
Registry status
Phase 2
Development phase
24 participants
Enrollment target
1
Study location

Study Summary

Background: \- Prostate cancer is the most common cancer type among men. Some prostate cancers respond to hormonal therapy. However, some cell characteristics of other prostate cancers cause it not to respond as well to these therapies. Researchers want to see if gadoxetate, a contrast agent used to help identify damaged liver tissue, can help tell these types of prostate cancer apart. It may be able to identify if a man has a type of prostate cancer for which hormone therapy may not work as well. Objectives: \- To see if gadoxetate can help identify different types of prostate cancers during imaging studies. Eligibility: \- Men at least 18 years of age who have prostate cancer. Participants will be having surgery to either remove the prostate or take tumor tissue samples. Design: * Participants will be screened with a physical exam and medical history. Blood samples will be collected. * Participants will have a magnetic resonance imaging (MRI) scan of the lower torso. They will receive gadoxetate during the MRI scan. * Participants who have surgery will have a sample of their tumor cells collected. Those who have a biopsy will provide cells from this biopsy for study. * Treatment will not be provided as part of this study.

Conditions Studied

Prostate Cancer

Interventions

  • DRUG Eovist

Study Locations (1)

Maryland

  • National Institutes of Health Clinical Center, 9000 Rockville Pike - Bethesda

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2013-05-14
Est. Completion 2016-12-08
Phase Phase 2

Sponsor

National Cancer Institute (NCI)

3,257 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01867424

The ClinicalTrials.gov registry entry for NCT01867424 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (96% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which Eovist is the first listed.

NCT01867424 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.

Frequently Asked Questions

What is clinical trial NCT01867424 about?

NCT01867424 is a clinical study titled "Gadoxetate Enhanced Imaging Study to Detect Prostate Cancer". Background: \- Prostate cancer is the most common cancer type among men. Some prostate cancers respond to hormonal therapy. However, some cell characteristics of other prostate cancers cause it not to respond as well to these therapies. Researchers want to see if gadoxetate, a contrast agent used t...

What is the current status of trial NCT01867424?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2013-05-14. Estimated completion is 2016-12-08.

What conditions does trial NCT01867424 study?

This clinical trial studies the following conditions: Prostate Cancer.

What interventions are being tested in trial NCT01867424?

The interventions under investigation include: Eovist (DRUG).

Who is sponsoring clinical trial NCT01867424?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01867424 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Prostate Cancer

All registered trials for this condition

Maryland

All trials with a study site in Maryland

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Related

Compare this shortlist side-by-side

Read our methodology - how this data is sourced, computed, and verified.
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.